Loading
Life sciences · Journal article
BMC Palliative Care · September 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a single case report of a 10-year-old child with terminal pelvic rhabdomyosarcoma and refractory cancer pain managed with tunneled patient-controlled epidural analgesia (PCEA) over 44 days. The case documents substantial subjective pain relief and improvement in quality-of-life measures, with minimal serious adverse effects, but provides no comparative evidence and cannot be generalized beyond the individual patient.
Single case report. 10-year-old female with terminal-stage pelvic rhabdomyosarcoma and multiple metastases presenting with refractory cancer-related visceral and breakthrough pain despite three weeks of intravenous opioid therapy, complicated by severe intestinal obstruction and cachexia rendering oral analgesics into…. Intervention: Tunneled patient-controlled epidural analgesia (PCEA) with subcutaneous tunneling technique using an individualized regimen of sufentanil, ropivacaine, lidocaine, dexmedetomidine, and dexamethasone.. n = 1.
VAS pain scores reduced from 4–6 to 0–1 between breakthrough episodes after PCEA initiation Breakthrough pain frequency decreased from 15–20 to 6–8 episodes per day with PCEA Rapid resolution of breakthrough pain within 3–6 minutes post-bolus
Long-term safety profile unknown; follow-up limited to patient's death at 44 days. Adverse effects limited to mild hypotension and nausea/vomiting; no serious complications such as infection during 44 days of therapy
This case suggests tunneled PCEA may be a feasible and well-tolerated option for pediatric terminal cancer pain refractory to conventional systemic opioids, potentially improving end-of-life quality of life. However, the single-case nature precludes recommendations for clinical practice; the approach requires evaluation in larger series before adoption.
Single pediatric case report describing a novel application of tunneled epidural analgesia in terminal cancer pain; demonstrates feasibility and tolerability but lacks comparative data and generalizability.
As stated by the source record.
Quoted from the source exactly as published.
This case suggests tunneled PCEA may be a feasible and well-tolerated option for pediatric terminal cancer pain refractory to conventional systemic opioids, potentially improving end-of-life quality of life. However, the single-case nature precludes recommendations for clinical practice; the approach requires evaluation in larger series before adoption.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Managing refractory cancer-related pain in pediatric patients with terminal-stage malignancies presents significant challenges, particularly when complicated by intestinal obstruction and cachexia. Conventional systemic analgesics often prove inadequate or intolerable. A 10-year-old female with pelvic rhabdomyosarcoma and multiple metastases developed refractory cancer-related visceral pain and breakthrough pain. After three weeks of standardized intravenous opioid therapy, analgesic effect remained unsatisfactory, and the patient developed severe intestinal obstruction and cachexia, rendering oral analgesics intolerable. Following multidisciplinary evaluation, tunneled patient-controlled epidural analgesia (PCEA) was initiated using a subcutaneous tunneling technique with an individualized regimen of sufentanil, ropivacaine, lidocaine, dexmedetomidine, and dexamethasone. The patient received PCEA for over one month, achieving significant pain relief with VAS scores reduced from 4 to 6 to 0–1 between breakthrough episodes. Breakthrough pain frequency decreased from 15 to 20 to 6–8 episodes per day, with rapid resolution within 3–6 min post-bolus. Muscle strength remained unaffected, activities of daily living and sleep quality improved markedly. Adverse effects were limited to mild hypotension and nausea/vomiting; no serious complications such as infection occurred. The patient maintained emotional stability and family interaction until peacefully passing away from tumor cachexia after 44 days of PCEA therapy. This case suggests that palliative tunneled PCEA may be safely and effectively used for pain management in children with terminal-stage refractory cancer-related visceral pain and breakthrough pain, potentially improving quality of life during the end-of-life period when conventional analgesic approaches fail.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.